A fierce response from readers

John Carroll, FierceBiotech Editor-in-ChiefWhen we ran the 2009 Fierce 15 report at the beginning of this week, we expected a big response. But even the optimists among the editorial crew here were surprised by the hard numbers. Monday provided the biggest single daily haul of page views in FierceBiotech's history. And Tuesday offered another bumper crop of readers. It all helped us make June the single biggest month ever for Web traffic.

It's always a lot of fun to go out and select a list of developers doing exciting things in the world of biotechnology, and we appreciate your clear interest in the project. As I mentioned earlier in the week, I start a new Fierce 15 once the report is posted. I've already received a number of suggestions and I encourage you to add your voice to the process.

On another note, we're preparing for the July 4th weekend and won't be publishing on Friday. We'll see you again on Monday. Enjoy the holiday. - John Carroll

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.